Hinge Health (NYSE:HNGE) Given New $67.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised its price target on Hinge Health to $67 (from $59) and maintains a "buy" rating, aligning with a MarketBeat consensus of a "Moderate Buy" and a roughly $67.40 average target across analysts.
• Strong Q1 results and raised guidance: Hinge reported $0.45 EPS vs. $0.12 consensus and $182.3M revenue (+47% YoY), then lifted FY2026 revenue guidance to $798–$804M while launching an FDA‑cleared Enso migraine program—key catalysts for the rally.
• Market reaction and caution: Shares jumped about 7% to $53.24 on heavy volume, but valuation/profitability remain concerns (negative P/E) and insiders have sold material stock positions recently, adding execution risk.

Hinge Health (NYSE:HNGE - Get Free Report) had its price objective hoisted by research analysts at Stifel Nicolaus from $59.00 to $67.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price target indicates a potential upside of 25.85% from the stock's current price.

Several other research firms also recently commented on HNGE. Piper Sandler reiterated an "overweight" rating and issued a $95.00 price target on shares of Hinge Health in a research report on Wednesday. Wall Street Zen downgraded shares of Hinge Health from a "buy" rating to a "hold" rating in a research report on Saturday. Raymond James Financial reiterated an "outperform" rating and issued a $70.00 price target on shares of Hinge Health in a research report on Wednesday. Royal Bank Of Canada upped their price objective on shares of Hinge Health from $55.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, Citigroup restated an "outperform" rating on shares of Hinge Health in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Hinge Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $67.40.

Hinge Health Trading Up 7.0%

HNGE stock traded up $3.49 on Wednesday, hitting $53.24. The company's stock had a trading volume of 3,523,538 shares, compared to its average volume of 1,206,973. The firm has a 50 day moving average of $42.20 and a two-hundred day moving average of $43.94. Hinge Health has a 1 year low of $30.08 and a 1 year high of $62.18. The stock has a market cap of $4.19 billion and a price-to-earnings ratio of -4.15.

Hinge Health (NYSE:HNGE - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.12 by $0.33. The business had revenue of $182.31 million during the quarter. During the same period last year, the business posted $1.30 EPS. Hinge Health's revenue was up 47.2% compared to the same quarter last year. As a group, equities analysts forecast that Hinge Health will post 0.78 EPS for the current fiscal year.

Insider Activity

In related news, Chairman Gabriel M.I. Mecklenburg sold 166,666 shares of the firm's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $45.32, for a total value of $7,553,303.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Antonio Perez sold 166,665 shares of the business's stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $40.26, for a total transaction of $6,709,932.90. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 442,670 shares of company stock worth $18,786,901 in the last 90 days. Corporate insiders own 18.92% of the company's stock.

Institutional Investors Weigh In On Hinge Health

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Hinge Health by 22.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company's stock worth $60,753,000 after acquiring an additional 228,234 shares in the last quarter. Tudor Investment Corp ET AL boosted its stake in shares of Hinge Health by 25.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company's stock worth $18,467,000 after acquiring an additional 77,464 shares in the last quarter. First Eagle Investment Management LLC purchased a new stake in shares of Hinge Health during the 3rd quarter worth approximately $4,074,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Hinge Health by 755.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company's stock worth $1,271,000 after acquiring an additional 24,155 shares in the last quarter. Finally, Braidwell LP purchased a new stake in shares of Hinge Health during the 3rd quarter worth approximately $44,686,000.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q1 beat — Hinge reported $182.3M revenue (+47% YoY) and $0.45 EPS vs. $0.12 consensus; management highlighted margin expansion and momentum. This is the primary catalyst for the rally. Business Wire: Q1 Results
• Positive Sentiment: Raised guidance — Company lifted FY2026 revenue guidance to $798M–$804M (well above prior consensus) and gave Q2 revenue guidance ~$194M–$196M, signaling durable demand and a clearer path to scale. Seeking Alpha: Guidance
• Positive Sentiment: Analyst upgrades — Multiple firms raised price targets (Citizens Jmp and Wells Fargo to $80; Needham to $63) and reiterated buy/overweight views, amplifying demand from institutional investors. Benzinga: Analyst Coverage
• Positive Sentiment: New product expansion — Hinge launched an FDA‑cleared Enso migraine program, which could broaden addressable market beyond MSK care and support future revenue diversification. Seeking Alpha: Enso Migraine
• Neutral Sentiment: Earnings call / transcripts available — Management commentary and slide deck are posted for details on customer metrics, margins and cadence of new program rollouts (useful for modeling). Seeking Alpha: Call Transcript
• Neutral Sentiment: Technical / volume signals — Trading volume has spiked versus average and RS/technical ratings improved ahead of the print, indicating elevated short‑term interest but also higher volatility. MSN: RS Rating
• Negative Sentiment: Valuation / profitability caveat — Despite the beat, Hinge's historical profitability metrics and a negative P/E reflect prior losses; execution must continue to justify higher multiples and the newer product initiatives. MarketBeat: Earnings Summary & Metrics

Hinge Health Company Profile

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.